Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Cell Cycle Regulation Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CDC20 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CDC20 Recombinant Protein (WD40 Domain / Full-length) High purity (>90%), Endotoxin controlled. Sequence Verified. Ideal for SPR/BLI binding assays. |
View CDC20 Products |
| Gene Delivery | CDC20 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and phenotypic rescue assays. |
View CDC20 Products |
| Benchmark Ab | Recombinant Anti-CDC20 Antibody High-affinity positive control for Western Blot, immunoprecipitation (IP), and IHC verification. |
View CDC20 Products |
| Validator | CDC20 siRNA Set Target-specific knockdown validation to confirm phenotypic dependency in cancer cell lines. |
View CDC20 Products |
| Related Target A | CDH1 (FZR1) Homologous APC/C co-activator. Critical for selectivity counter-screening to avoid off-target toxicity. |
View CDH1 Products |
| Related Target B | MAD2 (MAD2L1) Spindle assembly checkpoint protein that binds CDC20. Essential for protein-protein interaction (PPI) inhibition assays. |
View MAD2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling against homologous CDH1 | Highly purified recombinant CDH1 and CDC20 protein panels available, sequence verified by mass spectrometry. |
| Reconstitution of Spindle Assembly Checkpoint (SAC) complex | Biophysically characterized CDC20 and MAD2 proteins with native-like folding for robust binding assays. |
| Lack of reliable positive control antibodies | Recombinant sequence-derived benchmark antibodies ensuring batch-to-batch consistency. |
| Off-target toxicity validation in cell models | Validated siRNA sets and lentiviral delivery systems for controlled target knockdown and overexpression. |
Live CDC20 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CDC20 therapeutics is intensifying, with major players shifting focus from traditional small molecule inhibitors to targeted protein degradation (PROTACs) and RNA-based therapeutics. As first-generation mitotic arrest therapies reach the clinic, the next wave of R&D is targeting the specific protein-protein interactions (PPI) of CDC20 within the APC/C complex to minimize systemic hematological toxicities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTACs / Degraders | Academic institutions, Biotech startups | Solid Tumors, Triple-Negative Breast Cancer | Ternary complex formation assays (Need high-purity CDC20 recombinant protein) |
| Small Molecule Inhibitors | Oncology focused biopharma | Hematological Malignancies, Colorectal Cancer | Selectivity counter-screening (Need active CDH1 and CDC20 homolog proteins) |
| RNAi / ASOs | RNA therapeutics companies | Advanced Solid Tumors | Target validation and knockdown efficiency (Need validated CDC20 siRNA sets) |